Ih Chang, PhD

Vice President, Biometrics
AbbVie

Poster(s):

• (85) Efficacy and safety of fixed-dose tavapadon, an oral, once-daily, selective D1/D5 dopamine agonist for the treatment of early Parkinson’s disease
  Wednesday, October 29, 2025

• (86) Efficacy and safety of flexible-dose tavapadon, an orally administered, once-daily, selective D1/D5 dopamine agonist for the treatment of early Parkinson’s disease
  Wednesday, October 29, 2025

• (87) Efficacy and safety of tavapadon, an orally administered, once-daily, selective D1/D5 dopamine agonist, adjunctive to levodopa for treatment of Parkinson’s disease with motor fluctuations
  Wednesday, October 29, 2025